← feed

Is NCT03411122 results overdue?

Yes — results are overdue. Primary completion was 2018-01-23; the FDAAA-801 reporting deadline (2019-01-23) passed 2706 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

NCT IDNCT03411122 ↗
SponsorSumitomo Pharma America, Inc. (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-01-23 (ACTUAL)
Reporting deadline2019-01-23 (completion + 365d)
Days overdue2706
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 676ddb8062be1529… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03411122. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →